AVCO also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness in Clinical-Stage CellTech Developer Dedicated to Immune Effector Cell Therapy and Exosome Technology. Introducing Life Saving COVID-19 Diagnostics and Therapeutics.
New Treatment for Deadly Cytokine Storm in COVID-19 Patients.
Novel Technology to Efficiently Synthesize & Study Previously Difficult to Work With Drug Targets.
Technology Will Facilitate Drug Design for Cancer & Immune Diseases.
Study Published in September 2021 Issue of Journal Membranes.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeuticshealthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, AVCO is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics.
The researchers used computer-based models, developed at the University of Vienna, to identify factors that optimize the expression of membrane proteins in a cell-free, in-silico system, resulting in high protein yield. The AVCO study demonstrated the success of this method by showing the ability to manipulate and express a drug target membrane protein, a human voltage-dependent anion channel, at high yield.
The use of this novel AVCO technology can improve knowledge about receptors and other membrane proteins to better understand the biology of drug targets and to develop novel therapies, including immunotherapies for cancer.
The new technology is a direct result of a collaboration between AVCO and researchers at BOKU, Vienna, the University of Vienna, the Science for Life Laboratory within the Division of Nanobiotechnology at the KTH Royal Institute of Technology in Stockholm, Sweden and the Department of Biochemistry at the King Abdulaziz University in Jeddah, Saudi Arabia.
For more information on Avalon GloboCare Corp. (NASDAQ: AVCO) visit:
www.avalon-globocare.com